Home
About
Overview
Sharing Data
ORCID
Help
History (1)
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
View in:
PubMed
subject areas
Adenocarcinoma
Adult
Age Factors
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Cyclin-Dependent Kinase Inhibitor p16
DNA Methylation
Epigenesis, Genetic
Female
Genes, p16
Humans
Illinois
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Pneumonectomy
Prognosis
Radiography, Thoracic
Survival Rate
Treatment Outcome
authors with profiles
Michael Liptay
Sanjib Basu
Paolo Gattuso
Philip Bonomi